# TACE With Thermosensitive Nanogel Versus Embosphere for HCC

> **NCT06593964** · NA · RECRUITING · sponsor: **Zhongda Hospital** · enrollment: 188 (estimated)

## Conditions studied

- Unresectable Hepatocellular Carcinoma

## Interventions

- **DEVICE:** Thermosensitive Nanogel Embolic Agent

## Key facts

- **NCT ID:** NCT06593964
- **Lead sponsor:** Zhongda Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-10
- **Primary completion:** 2026-04-30
- **Final completion:** 2026-04-30
- **Target enrollment:** 188 (ESTIMATED)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06593964

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06593964, "TACE With Thermosensitive Nanogel Versus Embosphere for HCC". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT06593964. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*